MedWatch

Aamund regrets overly-ambitious strategy in Neurosearch

Had Neurosearch had two to three drugs for rare diseases, the biopharmaceutical corporation would have been a self-sustaining, profitable company today. That is the message delivered by Asger Aamund, who regrets that Neurosearch went exclusively after major drugs. Now he will focus on the development of niche medicine in Bavarian Nordic

From the outset, Neurosearch reached for the stars. The aim was drugs for widespread diseases such as cancer, depression and Alzheimer’s, but that strategy should have included another branch – niche medicine, admits Asger Aamund, who is co-founder and former chairman of the board in Neurosearch.

“When I look back at the history of Neurosearch, I would like to have had a couple of orphan drug programmes to start off with,” he points out.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Genmab-partner trækker sig fra samarbejde

Abbvie ønsker ikke længere at udvikle en fælles kræftkandidat med Genmab, men biotekselskabet skal stadig betale royalites af et eventuelt fremtidigt salg ved kommercialisering.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier